tyrosinase Inhibitors
2 drugsAbout tyrosinase
Tyrosinase is a copper-containing oxidase enzyme that catalyzes the initial steps in melanin synthesis. Its activity is central to melanogenesis, the process responsible for pigmentation in various organisms.
Tyrosinase is a drug target despite the absence of genetic evidence linking it to specific diseases. Its role in melanogenesis makes it relevant for therapeutic interventions.
Tyrosinase is targeted by two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, both marketed by AM REGENT for other therapeutic areas.
Top tyrosinase Drugs
AM REGENT is the only company with approved drugs targeting tyrosinase.
The lack of competition may indicate high barriers to entry or limited market potential.
tyrosinase Drug Modality Landscape
Modalities
Routes of Administration
tyrosinase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
tyrosinase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on tyrosinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
tyrosinase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approvals for tyrosinase were in 2020.
Recent approvals suggest renewed interest, but a short timeline may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on tyrosinase. A trial counts if an approved drug acting on tyrosinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.